Printer Friendly

Burst Biologics Launches Prospective Multicenter Clinical Study in Spinal Fusion.

M2 PHARMA-March 29, 2017-Burst Biologics Launches Prospective Multicenter Clinical Study in Spinal Fusion

(C)2017 M2 COMMUNICATIONS

- US-based biotechnology company Burst Biologics has received IRB approval to begin a multicentre prospective clinical study in spinal fusion patients, the company said.

This study will be conducted using BioBurst Fluid, a cellular allograft derived from umbilical cord blood which has shown very promising results in spinal fusion procedures.

Fifteen clinical sites will participate throughout the US with a total enrollment of 450 patients.

Popularity of cellular allografts has increased over the last decade. Figures show that the global spine biologics market is valued at USD 1.6bn and is expected to reach USD 2.2bn by 2022.

Burst Biologics is a biotechnology company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of tissue processing methodologies, all of which is done at the company's research facility.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Report
Date:Mar 29, 2017
Words:160
Previous Article:Digital Therapeutics Market to Reach USD 9.5bn by 2025, Research and Markets Forecasts.
Next Article:Behavioural Rehabilitation Market to Reach USD 313.9bn by 2025, Research and Markets Forecasts.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters